| | | | Market Reports
|
Multiplexed Diagnostics 2009 Market Report
Published March 2009
Multiplexed diagnostics are the long-awaited ascendance of ’omics into healthcare. The promise of multiple measurements to characterize complexity is finally being realized.
More>>
|
|
|
|
Cancer Personalized Medicine 2008
Published July 2008
The Cancer Personalized Medicine marketplace represents the paradigm for personalized medicine market evolution and Select Biosciences focuses in this report on the various commercialized cancer predictor tests, their current status, traction in the marketplace, quantitative market opportunities, and the factors that are driving as well as challenging the expansion of this space. Personalized Medicine, especially as it relates to Cancer, is undergoing significant growth and this report focuses i
More>>
|
|
|
|
Nanomedicine 2006-2011
Published June 2006
The purpose of this report is to examine the commercial prospects of nanotechnology in medicine – the fast-developing and increasingly lucrative field of nanomedicine. Nanotechnology has great potential to benefit - even revolutionise - the pharmaceutical, medical devices, diagnostics and imaging sectors.
More>>
|
|
|
|
World Guide to Bionanotechnology Industry and its Progression
Published October 2005
Nanotechnology, or the science of the small, holds enormous promise across all industries, not at least in life science. Since mid 90th there has been increasing intersection of two important scientific fields, nanotechnology and biotechnology, hence the name bionanotechnology.
More>>
|
|
|
|
The Impact of Nanotechnology in Drug Discovery
Published April 2005
This report discusses how nano-enabled discovery and validation technologies can expand the hit rate for promising compounds in the pipeline, and expedite their progress through to market.
More>>
|
|
|
|
Nano Drug Delivery
Published Published April 2005
This report examines the business opportunities that are being created by nano-engineered solutions for the drug delivery market. According to one source, approximately $65 billion in drug revenues every year are accounted for by pharmaceuticals with poor bio-availability which far too often results in higher patient costs and inefficient treatment but also, more importantly, increased risks of toxicity or even death.
More>>
|
|
|
| |
| |
|